Attachments
The United Kingdom’s bold and longstanding support to the Global Fund has played a critical role in fighting HIV, tuberculosis (TB) and malaria and ensuring a healthier, safer and more equitable future for all.
The Global Fund partnership has saved 59 million lives since 2002.
The Global Fund has disbursed over US$65 billion in more than 100 low- and middle-income countries since 2002 to fight HIV, TB, and malaria, strengthen health systems and build pandemic preparedness. Over half of our funding is dedicated to saving lives in Commonwealth countries, and 72% of our investments go towards countries in sub-Saharan Africa. With contributions from governments, foundations and the private sector, the Global Fund equitably and efficiently allocates funding to implementing countries, taking into account each country’s income level and disease burden. In the countries where we invest, the Global Fund partnership has reduced the combined death rate of HIV, TB, and malaria by more than half since 2002.
Our partnership
The UK is the third largest donor to the Global Fund and has contributed GBP 5.5 billion to date. The UK pledged GBP 1 billion for the Global Fund’s Seventh Replenishment in 2022, helping to leverage a record-breaking total of US$15.7 billion in pledges from public and private sector donors for the 2023-2025 period. With the UK’s support, the Global Fund works with local partners to strengthen health systems, advance gender equity and human rights, and leave no one behind.
The role of UK science
The UK is a global leader in scientific research and plays a critical role in global health efforts. UK science has been key in the fight against malaria, with UK institutions playing an important role in the development of the R21 and RTS,S malaria vaccines. Furthermore, the Innovative Vector Control Consortium (IVCC) and the London School of Hygiene & Tropical Medicine conducted years of research to develop mosquito nets using chlorfenapyr, a novel insecticide that has been crucial in combating insecticideresistant mosquitoes. Clinical trials and pilot studies showed that these new nets improved malaria control by up to 50% in countries facing insecticide resistance. The Global Fund, Unitaid and the U.S. President’s Malaria Initiative have contributed to the deployment of millions of these new nets across sub-Saharan Africa.